#Alteogen-Context

2 stories

Industry September 18, 2026 · View digest

Halozyme Prices Upsized $1.3 Billion 1.50% Convertible Senior Notes Due 2033 Offering to Refinance 2027-2028 Maturities and Fund ENHANZE Recombinant Hyaluronidase (rHuPH20) Platform Expansion

Halozyme Therapeutics (NASDAQ: HALO) priced Thursday September 17, 2026 an upsized $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 — increased from the previously announced $1.05 billion offering size announced Wednesday September 16, 2026. Terms: 1.50% coupon, semi-annual interest, initial conversion rate of 7.1509 shares per $1,000 principal (approximately $139.84 per share initial conversion price). Halozyme will use approximately $652.5 million of proceeds to repurchase existing convertible notes maturing in 2027 and 2028; the balance funds general corporate purposes including working capital and potential acquisitions. Offering close targeted September 22, 2026. Halozyme is the innovator of the ENHANZE recombinant hyaluronidase drug-delivery technology (proprietary rHuPH20 enzyme), which enables subcutaneous conversion of intravenously administered biologics — deployed by 10+ marketed products across partners including Roche (Herceptin SC, Phesgo, Ocrevus Zunovo, Tecentriq Hybreza), J&J (Darzalex Faspro, Rybrevant SC), Bristol Myers Squibb (Opdivo Qvantig), argenx (Vyvgart Hytrulo), and Alteogen's competing ALT-B4 platform after Roche's separate September 8 Alteogen licensing deal.

Industry September 17, 2026 · View digest

Dualitas Therapeutics Signs Research Collaboration and License Agreement With Roche Worth Up to $1 Billion ($36.5M Upfront) to Screen 300,000+ Bispecific Antibody Combinations for Immunology and Inflammation

Dualitas Therapeutics announced Thursday September 17, 2026 a research collaboration and license agreement with Roche worth up to $1 billion (including $36.5 million upfront plus research, development, and commercial milestone payments and tiered royalties) to discover and develop novel bispecific antibody therapeutics for immunology and inflammation (I&I) indications. Dualitas will apply its DualScreen Bispecific Discovery Engine — a proximity-biology-anchored functional-screening platform — to evaluate more than 300,000 novel bispecific combinations, one of the largest bispecific-screening endeavors publicly announced to date. Roche will assume responsibility for all subsequent preclinical development, regulatory, manufacturing, and commercial activities across the collaboration. The Dualitas platform positions bispecifics as vehicles for synergistic activities unattainable with conventional antibodies. The deal follows Roche's growing focus on I&I as one of its stated therapeutic pillars alongside oncology, neuroscience, and cardiometabolic disease. It also extends Roche's recent deal-making momentum, which included the September 8 Alteogen ALT-B4 subcutaneous-conversion licensing agreement worth up to $3.22 billion.